JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target

Janux Therapeutics, Inc. (NASDAQ:JANX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 14, JonesTrading analyst Soumit Roy maintained a bullish stance on Janux Therapeutics, Inc. (NASDAQ:JANX), giving it a Buy rating with a $90 price target. The analyst based the rating on the company’s promising developments and future potential.

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential

A rack of test tubes and beakers being stirred in a laboratory, as researchers analyze the data.

Janux Therapeutics, Inc. (NASDAQ:JANX) is expected to release additional data from its Phase 1 trials for JANX007 and JANX008 in H2 2025, which the analyst projects could affect its market position.

JANX007, a T cell-engaging antibody, is expected to be in competition with Pluvicto. Despite a complicated administration, Pluvicto already holds a considerable market share. However, the analyst reasoned that JANX007 could experience faster market adoption if it exhibits efficacy comparable to Pluvicto, which would positively impact Janux Therapeutics, Inc. (NASDAQ:JANX).

The analyst also noted that the safety profile of JANX007 would be critical, especially in regard to steroid use post-CRS resolution. Therefore, Roy reasoned that investor interest could grow with a favorable safety outcome.

Janux Therapeutics, Inc. (NASDAQ:JANX) is a preclinical stage biopharmaceutical company that develops therapeutics based on the Tumor Activated T Cell Engager platform technology. The company develops tumor-activated immunotherapies for cancer through two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr).

While we acknowledge the potential of JANX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.